These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7702986)

  • 1. In vitro models for testing of cytostatic agents in small cell lung cancer.
    Jensen PB; Sehested M
    Cancer Treat Res; 1995; 72():171-91. PubMed ID: 7702986
    [No Abstract]   [Full Text] [Related]  

  • 2. Doxorubicin sensitivity pattern in a panel of small-cell lung-cancer cell lines: correlation to etoposide and vincristine sensitivity and inverse correlation to carmustine sensitivity.
    Jensen PB; Roed H; Sehested M; Demant EJ; Vindeløv L; Christensen IJ; Hansen HH
    Cancer Chemother Pharmacol; 1992; 31(1):46-52. PubMed ID: 1360876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential sensitivity patterns in small cell lung cancer cell lines: detection and circumvention of resistance to topoisomerase II targeting drugs.
    Jensen PB
    Dan Med Bull; 1994 Nov; 41(5):475-88. PubMed ID: 7859516
    [No Abstract]   [Full Text] [Related]  

  • 4. Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines.
    Jensen PB; Christensen IJ; Sehested M; Hansen HH; Vindeløv L
    Br J Cancer; 1993 Feb; 67(2):311-20. PubMed ID: 8094293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multidrug resistance in lung cancer.
    Broxterman HJ; Versantvoort CH; Linn SC
    Cancer Treat Res; 1995; 72():193-222. PubMed ID: 7702987
    [No Abstract]   [Full Text] [Related]  

  • 6. Fractionated irradiation of H69 small-cell lung cancer cells causes stable radiation and drug resistance with increased MRP1, MRP2, and topoisomerase IIalpha expression.
    Henness S; Davey MW; Harvie RM; Davey RA
    Int J Radiat Oncol Biol Phys; 2002 Nov; 54(3):895-902. PubMed ID: 12377343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
    Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
    Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An etoposide-resistant lung cancer subline overexpresses the multidrug resistance-associated protein.
    Doyle LA; Ross DD; Ordonez JV; Yang W; Gao Y; Tong Y; Belani CP; Gutheil JC
    Br J Cancer; 1995 Sep; 72(3):535-42. PubMed ID: 7669558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical detection of DNA topoisomerase IIalpha, P-glycoprotein and multidrug resistance protein (MRP) in small-cell and non-small-cell lung cancer.
    Kreisholt J; Sorensen M; Jensen PB; Nielsen BS; Andersen CB; Sehested M
    Br J Cancer; 1998 May; 77(9):1469-73. PubMed ID: 9652763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationships among tumor responsiveness, cell sensitivity, doxorubicin cellular pharmacokinetics and drug-induced DNA alterations in two human small-cell lung cancer xenografts.
    Pratesi G; Capranico G; Binaschi M; De Isabella P; Pilotti S; Supino R; Zunino F
    Int J Cancer; 1990 Oct; 46(4):669-74. PubMed ID: 1976600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential functional imaging with technetium-99m hexakis-2-methoxyisobutylisonitrile and indium-111 octreotide: can we predict the response to chemotherapy in small cell lung cancer?
    Moretti JL; Caglar M; Boaziz C; Caillat-Vigneron N; Morere JF
    Eur J Nucl Med; 1995 Feb; 22(2):177-80. PubMed ID: 7758505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential expression of DNA topoisomerase II alpha and -beta in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4.
    Withoff S; de Vries EG; Keith WN; Nienhuis EF; van der Graaf WT; Uges DR; Mulder NH
    Br J Cancer; 1996 Dec; 74(12):1869-76. PubMed ID: 8980384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.
    Sorensen M; Sehested M; Jensen PB
    Br J Cancer; 1995 Aug; 72(2):399-404. PubMed ID: 7640225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of an etoposide-resistant human small-cell lung cancer cell line.
    Minato K; Kanzawa F; Nishio K; Nakagawa K; Fujiwara Y; Saijo N
    Cancer Chemother Pharmacol; 1990; 26(5):313-7. PubMed ID: 1976450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 9-Alkyl, morpholinyl anthracyclines in the circumvention of multidrug resistance.
    Coley HM; Twentyman PR; Workman P
    Eur J Cancer; 1990; 26(6):665-7. PubMed ID: 1975502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Combination chemosensitivity test of a human lung small cell carcinoma in vitro and in vivo].
    Inada T; Kubota T; Oishi T; Isobe Y; Fukutomi T; Kikuyama S; Shimoyama Y; Oka S; Ishibiki K; Abe O
    Nihon Gan Chiryo Gakkai Shi; 1987 Aug; 22(7):1361-6. PubMed ID: 2828496
    [No Abstract]   [Full Text] [Related]  

  • 17. Etoposide-induced cell cycle delay and arrest-dependent modulation of DNA topoisomerase II in small-cell lung cancer cells.
    Smith PJ; Souès S; Gottlieb T; Falk SJ; Watson JV; Osborne RJ; Bleehen NM
    Br J Cancer; 1994 Nov; 70(5):914-21. PubMed ID: 7947097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A study of cross-resistance pattern and expression of molecular markers of multidrug resistance in a human small-cell lung-cancer cell line selected with doxorubicin.
    Supino R; Binaschi M; Capranico G; Gambetta RA; Prosperi E; Sala E; Zunino F
    Int J Cancer; 1993 May; 54(2):309-14. PubMed ID: 8098017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment strategies in relation to drug action.
    Muggia FM; McVie G
    NCI Monogr; 1987; (4):129-33. PubMed ID: 2819724
    [No Abstract]   [Full Text] [Related]  

  • 20. Topoisomerase II alpha content and topoisomerase II catalytic activity cannot explain drug sensitivities to topoisomerase II inhibitors in lung cancer cell lines.
    Yamazaki K; Isobe H; Hanada T; Betsuyaku T; Hasegawa A; Hizawa N; Ogura S; Kawakami Y
    Cancer Chemother Pharmacol; 1997; 39(3):192-8. PubMed ID: 8996519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.